CHICAGO – Use of the gonadotropin-releasing hormone agonist goserelin during chemotherapy for early hormone receptor–negative breast cancer was associated with lower rates of ovarian failure and more...

Field of Interest: Oncology

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness